Our Team

Improving Cardiac Care

UltraSight was founded on a simple but powerful idea: to apply the power of geometrical deep learning to cardiac ultrasound and give the ability to scan patients to healthcare professionals everywhere to enable better patient care. Our goal is to make diagnostic imaging more accessible, allowing patients in various care settings to be diagnosed earlier in order to provide the right treatment at the right time.

We have assembled a talented group of highly experienced software engineers, clinicians and business experts. We created a team united in the mission to improve cardiac care by putting cardiac ultrasound in the hands of every healthcare provider.

Executive Management

Davidi Vortman

CEO

+

Davidi Vortman

CEO

Davidi Vortman is the CEO of UltraSight. With over 20 years of experience as a tech entrepreneur, Davidi has founded and grown several public and private high technology companies such as Lumos Global, Comverse Technologies, and NICE Systems (NASDAQ: NICE), and has a proven track record for managing ventures with consistent revenue growth. He holds a B.S.c in Computer Science from the Hebrew University and an MBA from Kellogg-Recanati at Northwestern University.

Itay Kezurer

Co-Founder and Chief Technology Officer

+

Itay Kezurer

Co-Founder and Chief Technology Officer

Itay Kezurer is Co-Founder and Chief Technology Officer of UltraSight. Itay brings algorithm development in the field of computer vision and computer graphics knowledge to the team. Prior to UltraSight, Itay was an algorithmic engineer at Elbit Systems. Itay holds an MSc in Applied Mathematics and Computer Science from the Weizmann Institute of Science, and a BSc (cum laude) in Electrical Engineering from Ben-Gurion University. 

Achi Ludomirsky, MD

Co-Founder and Chief Medical Officer

+

Achi Ludomirsky, MD

Co-Founder and Chief Medical Officer

Achi Ludomirsky is Co-Founder and Chief Medical Officer at UltraSight. Achi is also a professor of pediatric cardiology and pediatrics and is the associate chair of Pediatric Outreach at NYU School of Medicine. Dr. Ludomirsky is a pioneer in fetal and pediatric heart imaging and is internationally known for his instrumental role in the development of novel imaging and therapeutic procedures for fetuses and children with congenital heart disease.

Yaron Lipman, PhD

Co-Founder and Chief Scientific Officer

+

Yaron Lipman, PhD

Co-Founder and Chief Scientific Officer

Yaron Lipman is Co-Founder and Chief Scientific Officer of UltraSight. Yaron is also an associate professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, Israel. Yaron’s research focuses on geometric modeling and processing, shape comparison and analysis, and geometric deep learning. Yaron holds a PhD from Tel Aviv University and did his postdoctoral work at Princeton University.

Xen Mendelsohn Aderka

VP Marketing

+

Xen Mendelsohn Aderka

VP Marketing

Xen Mendelsohn Aderka is Vice President of Marketing at UltraSight. Xen is a marketing professional with 17 years of experience in medical technology and high technology. Previously, Xen was INSIGHTEC’s VP of Marketing where she built a global marketing organization and provided the leadership, strategy and execution for global marketing programs.  Xen holds a B.A. in Journalism & Communication and Theater Arts from The Hebrew University.

Raanan Gonen

VP R&D

+

Raanan Gonen

VP R&D

Raanan Gonen is UltraSight’s Vice President of Research and Development. He is an experienced AI and machine learning architect and enterprise software professional. He has led the design of multiple AI-based products and research projects and has a proven ability to build architecture from A-Z to create a final production design. Raanan holds a BSc in Computer Science from the Tel Aviv University.

Danny Spiegelstein, MD

VP Medical

+

Danny Spiegelstein, MD

VP Medical

Danny Spiegelstein MD is UltraSight’s Vice President of Medical. Dr. Spiegelstein has 20+ years of medical experience in cardiovascular invasive medicine. He is an experienced clinical research investigator, managing protocols and operations in compliance with GMP and other regulatory requirements. Prior to UltraSight, Dr. Spiegelstein served as a consultant for medical start-ups in cardiology.

Noa Avisar, PhD

VP Clinical and Regulatory Affairs

+

Noa Avisar, PhD

VP Clinical and Regulatory Affairs

Noa Avisar is UltraSight’s Vice President of Clinical Affairs and has 20 years of experience in drug and device development. She led the clinical development of oncology and neurology projects at Teva Pharmaceuticals and was the project development leader for various drugs from oncology to autoimmunology. Dr. Avisar has published 13 papers in scientific journals. She holds a Ph.D. in molecular biology from Tel Aviv University with postdoctoral research in molecular immunobiology from University of California Santa Barbara.

Sarah Mowery, MPAS, PA-C

VP Operations

+

Sarah Mowery, MPAS, PA-C

VP Operations

Sarah Mowery is the Vice President of Operations at UltraSight. A board-certified clinician, with over 15 years in healthcare, Sarah brings a proven track record of building innovative and disruptive healthcare services at scale, enhancing patient and provider experience, improving accessibility to high quality healthcare, and driving organizational financial performance. Prior to UltraSight, Sarah held the role of Head of Product at Clinical Trial Services, a clinical research startup within CVS Health. 

Board Members

Doron Birger

Chairman of the Board

+

Doron Birger

Chairman of the Board

Doron is chairman, director and advisor to a variety of technology companies. Previously, Doron was the CEO of Elron Electronic Industries (NASDAQ: ELRNF and TASE ) and chairman and director of Given Imaging (NASDAQ: GIVN) until its sale to Covidian.

Ruth Atherton, PhD, JD

Board Member

+

Ruth Atherton, PhD, JD

Board Member

Dr. Atherton serves as Chief Legal Officer for The Commons Project Foundation. Previously, she served as Deputy General Counsel for the Bill & Melinda Gates Foundation. Prior to the Gates Foundation, Dr. Atherton served as in-house Sr. Corporate & IP litigation at Fitzpatrick Cella Harper & Scinto. She holds a Ph.D in Cell & Molecular Biology and a J.D. from  Fordam Law.

Rick Heinick

Board Member

+

Rick Heinick

Board Member

Rick Heinick is an active board member, investor and entrepreneur in leading medical devices and pharmaceutical companies. Currently, Rick serves on the boards of TearClear, Lentechs, Theroptix and TruIris.

Yigal Erlich

Board Member

+

Yigal Erlich

Board Member

Yigal Erlich is the founding father of the Israeli venture capital industry and one of the most prominent figures in the Israeli high-tech arena. Yigal also served as Chief Scientist of Israel’s Ministry of Industry and Trade.

Gilad Glick

Board Member

+

Gilad Glick

Board Member

Gilad Glick is the Vice President, Venture Investments at Johnson & Johnson – Pharma Israel and MedTech Israel and Europe, where he leads a team of investors to initiate and manage equity investments to drive business innovation and deliver new and sustainable business for the Pharma and MedTech sectors. 

Team

Issahar Weiss 

Senior Software Developer

Ganit Porat Stoler

Senior Software Developer

Igal Blechman

Director of Finance

Adam Doron, PhD

Deep Learning Applied Researcher

Talia Amar

Deep Learning Applied Researcher

Jonathan Shlomi, PhD

Deep Learning Applied Researcher

Niv Nissani

Software Engineer

Inna Kucherov

Quality Engineer

Ilan Ohayon

Financial Controller

Madeleine Truitt

Marketing Manager

Israela Rimon

Administrative Manager